Effect of propranolol on secretin-induced gastrin release and secretin-induced tachycardia in patients with the Zollinger-Ellison syndrome.
The mechanism for secretin-induced gastrin release in the Zollinger-Ellison syndrome is uncertain. We evaluated whether the stimulatory effect of intravenous secretin on gastrin release was partly mediated through a beta-adrenergic stimulatory mechanism. Serum gastrin concentrations and heart rate were monitored in six patients with the Zollinger-Ellison syndrome. Secretin (2 clinical units/kg) increased mean serum gastrin concentrations from 1558 pg/ml basally to a peak of 3683 pg/ml (136% above baseline). This increase was not altered by pretreatment with 2 mg of propranolol intravenously, a dose which in previous studies blocked terbutaline-induced gastrin release. Secretin increased heart rate by 14 beats/min (20% above base-line) and this also was not altered by propranolol pretreatment. Thus, the stimulatory effects of secretin on gastrinoma cells and the heart do not appear to be mediated by beta-adrenergic receptors.
Goldschmeidt
M
M
Medical Service, Department of Veterans Affairs Medical Center, Dallas, Texas 75216.
Redfern
J S
JS
Feldman
M
M
D000328:Adult; D000368:Aged; D005755:Gastrins / Q000097:blood / Q000378:metabolism*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000494:pharmacology*; D011863:Radioimmunoassay; D012633:Secretin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D013610:Tachycardia / Q000209:etiology* / Q000503:physiopathology; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D005755:Gastrins; D012633:Secretin; D011433:Propranolol